Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC)

被引：0
|
作者：
Galle, P. R. [1 ]
Crysler, O., V [2 ]
Yarchoan, M. [3 ]
Furuse, J. [4 ]
Sukeepaisarnjaroen, W. [5 ]
Thinh, N. T. [6 ]
Masi, G. [7 ]
Lim, H. Y. [8 ]
Varela, M. [9 ]
Gupta, C. [10 ]
Makowsky, M. [11 ]
Negro, A. [11 ]
Abou-Alfa, G. K. [12 ,13 ]
机构：
[1] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Mainz, Germany
[2] Univ Michigan, Ann Arbor, MI USA
[3] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[5] Khon Kaen Univ, Khon Kaen, Thailand
[6] 108 Cent Mil Hosp, Hanoi, Vietnam
[7] Pisa Univ, Pisa, Italy
[8] Sungkyunkwan Univ, Seoul, South Korea
[9] Univ Oviedo, IUOPA, ISPA, FINBA, Oviedo, Spain
[10] AstraZeneca, Wilmington, DE USA
[11] AstraZeneca, Gaithersburg, MD USA
[12] Cornell Univ, New York, NY USA
[13] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V899
引用
收藏
页码：129 / 129
页数：1
相关论文
共 50 条
  • [21] Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Sangro, B.
    Chan, S.
    Kelley, R.
    Lau, G.
    Kudo, M.
    Sukeepaisarnjaroen, W.
    De Toni, E.
    Furuse, J.
    Kang, Y.
    Galle, P.
    Rimassa, L.
    Heurgue, A.
    Tam, V.
    Dao, T.
    Thungappa, S.
    Breder, V.
    Ostapenko, Y.
    Reig, M.
    Makowsky, M.
    Gupta, C.
    Negro, A.
    Abou-Alfa, G.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S168 - S168
  • [22] T-cell receptor pharmacodynamics associated with survival and response to tremelimumab (T) in combination with durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
    McCoon, Patricia
    Lee, Young S.
    Kelley, Robin Kate
    Guthrie, Violeta Beleva
    Wu, Song
    Bien, Stephanie A.
    Negro, Alejandra
    He, Philip
    Kurland, John
    Barrett, J. Carl
    Pilataxi, Fernanda
    Ching, Steven
    Abou-Alfa, Ghassan K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] T cell receptor and immune gene expression pharmacodynamics for durvalumab monotherapy and in combination with tremelimumab or bevacizumab in unresectable hepatocellular carcinoma (uHCC)
    Kelley, Robin Kate
    Lee, Young S.
    Conway, James
    Kurland, John F.
    Negro, Alejandra
    McCoon, Patricia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Low immunogenicity and favorable safety seen with novel regimen of tremelimumab (T) plus durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)
    Kelley, R. K.
    Negro, A.
    Chen, C.
    Ali, S.
    Standifer, N.
    Watras, M.
    Evans, B.
    Abou-Alfa, G. K.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1429 - S1429
  • [25] Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Sangro, B.
    Chan, S. L.
    Kelley, R. K.
    Lau, G.
    Kudo, M.
    Sukeepaisarnjaroen, W.
    Yarchoan, M.
    De Toni, E. N.
    Furuse, J.
    Kang, Y. K.
    Galle, P. R.
    Rimassa, L.
    Heurgue, A.
    Tam, V. C.
    Van Dao, T.
    Thungappa, S. C.
    Breder, V.
    Ostapenko, Y.
    Reig, M.
    Makowsky, M.
    Paskow, M. J.
    Gupta, C.
    Kurland, J. F.
    Negro, A.
    Abou-Alfa, G. K.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 (05) : 448 - 457
  • [26] Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Sangro, Bruno
    Morse, Michael
    Zhu, Andrew X.
    Kim, Richard D.
    Cheng, Ann-Lii
    Kudo, Masatoshi
    Kang, Yoon-Koo
    Chan, Stephen L.
    Antal, Joyce
    Boice, Jillian
    Xiao, Feng
    Morris, Shannon R.
    Bendell, Johanna
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.
    Kelley, Robin Kate
    Abou-Alfa, Ghassan K.
    Bendel, Johanna C.
    Kim, Tae -You
    Borad, Mitesh J.
    Yong, Wei-Peng
    Morse, Michael
    Kang, Yoon-Koo
    Rebelatto, Marlon
    Makowsky, Mallory
    Xiao, Feng
    Morris, Shannon R.
    Sangro, Bruno
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
    Kelley, Robin Kate
    Sangro, Bruno
    Harris, William
    Ikeda, Masafumi
    Okusaka, Takuji
    Kang, Yoon-Koo
    Qin, Shukui
    Tai, David W-M
    Lim, Ho Yeong
    Yau, Thomas
    Yong, Wei-Peng
    Cheng, Ann-Lii
    Gasbarrini, Antonio
    Damian, Silvia
    Bruix, Jordi
    Borad, Mitesh
    Bendell, Johanna
    Kim, Tae-You
    Standifer, Nathan
    He, Philip
    Makowsky, Mallory
    Negro, Alejandra
    Kudo, Masatoshi
    Abou-Alfa, Ghassan K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (27) : 2991 - +
  • [29] MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) OF SINGLE TREMELIMUMAB REGULAR INTERVAL DURVALUMAB (STRIDE) VERSUS ATEZOLIZUMAB WITH BEVACIZUMAB (A plus B) FOR THE TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC)
    Qin, L.
    Chan, S.
    Le Nouveau, P.
    Gaughan, A.
    Gauthier, A.
    Makowsky, M.
    Kurland, J.
    Negro, A.
    Palmer, S.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S27 - S27
  • [30] A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).
    Zhu, Andrew X.
    Finn, Richard S.
    Ikeda, Masafumi
    Sung, Max W.
    Baron, Ari David
    Kudo, Masatoshi
    Okusaka, Takuji
    Kobayashi, Masahiro
    Kumada, Hiromitsu
    Kaneko, Shuichi
    Pracht, Marc
    Mamontov, Konstantin
    Meyer, Tim
    Mody, Kalgi
    Kubota, Tomoki
    Dutcus, Corina E.
    Saito, Kenichi
    Siegel, Abby B.
    Dubrovsky, Leonid
    Llovet, Josep M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345